Should You Get the Galleri Cancer Blood Test?
If you're 50 or older and worried about the cancers no one screens for, Galleri is a reasonable add-on. An FDA advisory panel just voted 7-2-1 that its benefits outweigh its risks. It's still a prescription screen you pay for out of pocket at $949, not a replacement for your mammogram, colonoscopy, or lung CT. When the test fires, it points to the right organ about 85% of the time. The catch: it misses most stage I cancers, and a positive result is more often wrong than right in healthy adults.
Roughly two-thirds of cancer deaths in the United States come from tumors with no recommended screening program at all: pancreatic, ovarian, esophageal, liver, bile duct, small intestine, kidney. Standard screening covers breast, cervical, colon, prostate, and lung for eligible smokers. Everything else is caught when it causes symptoms, which usually means late. Galleri is the first blood test with a credible signal against that blind spot, which is the reason to consider it at all.
On September 23, 2026, the FDA's Molecular and Clinical Genetics Devices Panel voted 7-2 with one abstention that Galleri's benefits outweigh its risks. Safety was unanimous. Effectiveness split 6-4. The FDA isn't bound by the vote, and a final decision on premarket approval is expected in coming months. For now, Galleri is what it has been since 2021: a prescription lab-developed test at a $949 list price, not covered by Medicare or most private insurance.
How the test works
Tumors shed DNA into your bloodstream as their cells die. Galleri reads chemical tags on that DNA called methylation marks. Cancer cells carry distinctive methylation patterns, and different tissues carry different patterns from birth, so a single blood draw can both flag that cancer is present and predict where it came from. The report either says a signal was detected or it wasn't; if it was, it names the one or two most likely organs of origin to guide the workup.
What PATHFINDER showed
PATHFINDER, published in The Lancet in 2023, is the largest prospective screening study of Galleri in adults 50 and older with no known cancer. Among 6,621 people, the test flagged a signal in 1.4%. When it flagged, it named the right organ on the first prediction about 85% of the time. Nearly half of confirmed cancers were caught at stage I or II, and the test picked up lethal cancers of the pancreas, bile duct, and small intestine that today's screening programs don't touch. Specificity was 99.1%.
Two harder numbers cut the other way. Only about 4 in 10 positive signals turned out to be cancer, so most positives were wrong. And stage I sensitivity, the number that matters most for a screening test whose whole promise is finding disease early, was only about 17%. It rises to about 40% at stage II, 77% at stage III, and 90% at stage IV. A negative Galleri does not mean cancer-free. If you're in the size range where a tumor is most curable, the test is likely to miss it.
There is a cost to a false alarm. In PATHFINDER, people whose signal turned out to be nothing spent a median 162 days getting to a clear answer, versus 57 days for people who did have cancer. About 9 in 10 got imaging, roughly 3 in 10 had an invasive procedure, and one had an unnecessary surgery. Real-world data from more than 111,000 commercial tests since launch put the positive predictive value closer to 49%, which is roughly a coin flip once the test is in routine practice.
The NHS-Galleri readout: encouraging, not proof
The trial designed to answer whether Galleri saves lives is NHS-Galleri, a randomized study of about 140,000 UK adults aged 50 to 77. Full results presented at ASCO 2026 showed a greater than 20% reduction in stage IV diagnoses at the first screen, and roughly four times as many cancers caught in the screened arm as with standard screening alone. That is the kind of downstaging Galleri is supposed to produce.
But the trial missed its prespecified primary endpoint, a combined reduction in stage III and IV cancers. That's why the panel split 6-4 on effectiveness, and why no guideline body recommends routine use. History is a warning here. The UKCTOCS ovarian cancer trial cut late-stage disease by about 10% and still showed no mortality benefit over 15 years. Downstaging is necessary but not sufficient. Cancer-specific mortality data from NHS-Galleri won't arrive until 3 and 6 years after the final screen.
Where Galleri fits next to the screens you already qualify for
The comparison isn't really Galleri versus mammography. It's Galleri versus no screen at all for the cancers that kill the most people. A mammogram won't find pancreatic cancer. A colonoscopy won't find ovarian cancer. A low-dose lung CT won't find bile duct cancer. For those diseases, Galleri is the only screening tool that exists outside of high-risk surveillance programs for people with specific genetic syndromes.
| Screen | What it looks for | Early-stage sensitivity | Cost and coverage | Mortality evidence |
|---|---|---|---|---|
| Galleri | 50+ cancer types via cfDNA methylation | About 17% at stage I, 40% at stage II | $949; not covered by Medicare or most insurance | Not yet proven; RCT missed primary endpoint |
| Mammogram | Breast cancer | Established for early-stage breast cancer | Covered by Medicare and most insurance | Proven |
| Low-dose CT | Lung cancer in eligible smokers | Established for early-stage lung cancer | Covered for eligible smokers | Proven |
| Colonoscopy or stool DNA | Colorectal cancer and precancerous polyps | Established; colonoscopy also removes polyps | Covered by Medicare and most insurance | Proven |
So who is this for
If you're under 50 and average-risk, the case is thin. Galleri hasn't been validated in younger adults, cancer prevalence is lower, and the false-alarm math gets worse the healthier your baseline population is.
If you're 50 or older and specifically worried about the cancers no one screens for, especially with a family history of pancreatic, ovarian, or upper GI cancer, an inherited cancer syndrome, heavy tobacco exposure, or another risk factor that puts you above the population baseline, Galleri is a defensible add-on. Go in understanding four things. It will miss most stage I cancers, so a negative result is not a clean bill of health. A positive result is more likely wrong than right in a healthy adult, and it will trigger months of imaging, possibly a procedure, to sort out. It does not replace your mammogram, your colonoscopy, or your lung CT. And at $949 out of pocket, with Medicare coverage not possible before 2028 under the Nancy Gardner Sewell Act (and only if the test is FDA-approved and CMS determines coverage is appropriate), you are paying for a test whose mortality benefit has not been proven.
Population odds are not your individual answer. The population effect is modest. The effect on that person is everything.
What would change the answer
Two results. First, the NHS-Galleri mortality readout at 3 and 6 years post-final-screen, showing the stage IV downstaging translates into fewer cancer deaths. Second, formal FDA approval paired with a USPSTF endorsement, which would drive insurance coverage and drop the out-of-pocket barrier. If mortality data don't materialize, or if long-term follow-up shows the test is quietly picking up indolent tumors that would never have hurt anyone, the case for broad use collapses. Until then, Galleri is what the panel called it: a test whose benefits outweigh its risks for a specific person, in a specific age band, who understands what a negative result does not mean.